Literature DB >> 11557167

Naltrexone dampens ethanol-induced cardiovascular and hypothalamic- pituitary-adrenal axis activation.

M E McCaul1, G S Wand, R Stauffer, S M Lee, C A Rohde.   

Abstract

Alcohol ingestion activates the autonomic nervous system and the hypothalamic-pituitary-adrenal axis. This study examined naltrexone effects on alcohol-induced increases in physiological responses and their association with alcohol liking. Using a within-subjects design, heavy drinking men (N = 19) were maintained on each of three naltrexone doses (0, 50, and 100 mg, p.o.) over an 8-day inpatient stay. Within each naltrexone dose, subjects had three alcohol challenge sessions (none, moderate, high) in random order. Autonomic, subjective and endocrine measurements were collected regularly prior to and following alcohol administration. High-dose alcohol ingestion increased heart rate, diastolic blood pressure, skin temperature, ACTH, cortisol and liking of drink effects; responses following the moderate alcohol dose were less consistent. Naltrexone significantly dampened alcohol-induced increases in heart rate, diastolic blood pressure, hormone levels and subjective liking of drink effects. This dampening of cardiovascular and hormonal responses may contribute to the therapeutic effectiveness of naltrexone for reducing alcohol liking and decreasing relapse in alcohol-dependent persons.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557167     DOI: 10.1016/S0893-133X(01)00241-X

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  29 in total

Review 1.  Extended-release intramuscular naltrexone.

Authors:  Tracy Swainston Harrison; Greg L Plosker; Susan J Keam
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.

Authors:  Stephanie S O'Malley; Suchitra Krishnan-Sarin; Sherry A McKee; Robert F Leeman; Ned L Cooney; Boris Meandzija; Ran Wu; Robert W Makuch
Journal:  Int J Neuropsychopharmacol       Date:  2008-09-17       Impact factor: 5.176

3.  Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects.

Authors:  Elise M Weerts; Gary S Wand; Hiroto Kuwabara; Cynthia A Munro; Robert F Dannals; John Hilton; J James Frost; Mary E McCaul
Journal:  Alcohol Clin Exp Res       Date:  2011-06-20       Impact factor: 3.455

Review 4.  Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review.

Authors:  Martyna Sawicka; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2017-05-24

5.  Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.

Authors:  Spencer Bujarski; James MacKillop; Lara A Ray
Journal:  Exp Clin Psychopharmacol       Date:  2012-03-19       Impact factor: 3.157

6.  Examining naltrexone and alcohol effects in a minority population: results from an initial human laboratory study.

Authors:  Jennifer G Plebani; David W Oslin; Kevin G Lynch
Journal:  Am J Addict       Date:  2011-05-31

Review 7.  Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism.

Authors:  Lara A Ray; James Mackillop; Peter M Monti
Journal:  Subst Use Misuse       Date:  2010-09       Impact factor: 2.164

8.  Self-administration of methohexital, midazolam and ethanol: effects on the pituitary-adrenal axis in rhesus monkeys.

Authors:  Jillian H Broadbear; Gail Winger; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2004-08-21       Impact factor: 4.530

9.  Effects of naltrexone on cortisol levels in heavy drinkers.

Authors:  Lara A Ray; James Mackillop; Lorenzo Leggio; Marilee Morgan; Kent E Hutchison
Journal:  Pharmacol Biochem Behav       Date:  2008-09-13       Impact factor: 3.533

10.  Attributions of change and self-efficacy in a randomized controlled trial of medication and psychotherapy for problem drinking.

Authors:  Katherine Schaumberg; Alexis Kuerbis; Jon Morgenstern; Frederick Muench
Journal:  Behav Ther       Date:  2012-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.